Sun, Feb 1, 2015, 10:19 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

ACADIA Pharmaceuticals Inc. Message Board

  • ovaltien5000 ovaltien5000 Aug 1, 2009 1:51 AM Flag

    Pimavanserin article that will blow you away!

    I see that all the shorts have descended on this board and spewing their normal garbage. Read this article about Pimavanserin and you won't fall prey to any of the shorties idiotic games. The phase III are going to be robust and we're all going to make a lot of money as long as we stick to our guns and don't listen to paid bashers like Mutasian and unscrupulous websites like the street. Bump this article a few times so that newbies can read it also.
    http://www.docguide.com/news/content.nsf/news/852571020057CCF68525757C00528875?OpenDocument&id=48DDE4A73E09A969852568880078C249&c=Parkinson's&count=10

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Its all in the fine print....pump up the volume, time to let the world know what we got here.

    • Unfortunately, all biotechs will be hit tomorrow due to the SVNT denial.

    • Sometimes you just got to trust your gut, the chart, and articles that have facts.

      Unfortunately, there are too many financial interests to trust certain media personalities.

      My positives far outweigh any negatives.... I am sure we will get some direction during the earnings call.

      In the end, you can only trust your own judgement and faith in yourself. The successful investor is one who can control his/her emotions and look at both sides of the argument.

      My post is not a reccomendation.... more of a banter to pass the time.

      GLTA

    • Thanks for posting the article.

    • irenecarol@bellsouth.net irenecarol Aug 1, 2009 7:42 PM Flag

      i am getting sick of ALL the message boards. So much negativity and it makes me wonder why these folks are on the boards bashiing a stock they own, or do they really own any shares? crazy huh?

    • Very nice article....

      Thanks for the post.

    • Thank you for posting this.

    • Following points may lead to a phase 3 clinical trial failure. anyone more knowledgeable please shed more light on these points :



      1. Primary outcome analysis used the Unified PD Rating Scale (UPDRS) parts II (activities of daily living) and III (motor examination). Further secondary assessments included Scale for the Assessment of Positive Symptoms (SAPS), Clinical Global Impression Scale-severity (CGI-S), and the Parkinson's Psychosis Rating Scale (PPRS).

      2. For the safety analysis, 72.4% and 77.4% of patients, respectively, reported adverse events (AEs), although the 4 serious AEs reported were all considered not related to the study drug. With pimavanserin, the most common AEs were somnolence, oedema, and blood urea increase, while placebo AEs were hallucinations, dizziness, fall, headache, confusion, and hypotension.

      Williams noted that based on these data, 39 of these patients have since entered an ongoing open-label, safety extension study. After 48 months in this extension study, pimavanserin remains well tolerated at doses up to 60 mg daily.

      • 1 Reply to johnmajor44
      • JohnMajor44 nobody needs to answer any of your questions because your only here to bash the stock in the first place. Every single message in your view messages is you bashing a stock. It would take about 400 pages to explain to you the SAPS, UPDRS, CGI-S and PPRS ratings scale. Why don't you just go to Wikipedia or god forbid read a book.

        The safety analysis you gave 72.4% and 77.4% is actually deemed very exceptable when you consider that you are dealing with people that are suffering from hallucinations and psychosis. The safety of the drug was established before submitting the initial IND and in phase I toxicology testing.

        A few AE's are to be expected in every test and the fact that none of them were attributed to Pimavanserin is an extremely good sign. The best indicator from the study is that a high level (39) choose to stay on the drug even after the study concluded. That tells me that the drug is working good for them, they're not having negative side effects, and they feel safe on the medication.

        Not to mention the most important point of all which is that the drug is doing exactly what it's designed to do: quickly arrest boughts of psychotic episodes and normalize patients cognitive function. Plus the drug achieves these results two weeks quicker then the Standard of Care meaning two weeks less in the hospital for patients and two weeks less of medical bills. Cost effectiveness gaurantees that it will ALWAYS be chosen over the current SOC.

    • sellers; three other stocks had strange drops in price and soon recovered dndn,htrn,medx,since acad recoverd from it's low to $4.16 ah this could be trick to get people to sell

    • For effects on psychosis, greater improvements were seen for pimavanserin treatment over placebo. In particular, Williams indicated significant improvements in the SAPS combination score for hallucination and delusion as percentage change from baseline of 40% and 11%, respectively (P < .05). Similarly, the UPDRS-I scores for mentation, behaviour, and mood were significantly improved by pimavanserin treatment (P < .05).

      SIGNIFICANT IMPROVEMENTS!!!!!!!!! It's a dead issue people. That's why large investors piled in on those $7.50 calls and sent this stock soaring. Hold your shares or acquire. Make sure your sell orders are set at $20 so short sellers can't borrow your shares. Don't be stupid and listen to those who are going to trick you into selling like they did with HGSI. The only legitimint source of information for Pimavanserin is the phase II testing, and the phase II testing says it showed significant improvements in behavior, mood, and mentation. All three being huge unmet needs for Parkinson. $10.00 is not only possible by calls expiration on Sept 21 but extremely likely.

      Hold your ground
      Oval

 
ACAD
30.43-0.62(-2.00%)Jan 30 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.